Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Fludarabine, cyclophosphamide, and melphalan (FCM) preconditioning in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia: Update of a prospective, multicenter, single-arm clinical study

Xiaoping Li, Yali Zhou, Bo Nie, Peng Zhao, Jiong Hu, Chun Wang, Hao Zhang, Xiaolin Yin, Wang Sanbin

Blood (2025) 146 (Supplement 1): 4201.

https://doi.org/10.1182/blood-2025-4201

Published: 2025

Journal Articles

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Blood (2025) 146 (Supplement 1): 5954.

https://doi.org/10.1182/blood-2025-5954

Published: 2025

Journal Articles

Carfilzomib Augmented with high-dose melphalan conditioning regimen Enhances Response in patients with multiple myeloma eligible for ASCT：an investigator-initiated, prospective, multicenter study

Xianyi Wu, Xiaotao Wang, Yali Zhou, Yuchan He, Fujun Qu, Tongtong Chen

Blood (2025) 146 (Supplement 1): 2256.

https://doi.org/10.1182/blood-2025-2256

Published: 2025

Journal Articles

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Blood (2025) 146 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2025-1042

Published: 2025

Journal Articles

A novel reduce toxity myeloablative conditioning regimen f-BMT improves efficacy and safety of allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent thalassemia: A multicenter clinical trial

Guiping Liao, Dongmei Liu, Yali Zhou, Xianyi Wu, Ruihong Dong, Beibei Yang, Changqing Wei, Lan Deng, Xiaotao Wang, Xiaolin Yin

Blood (2025) 146 (Supplement 1): 729.

https://doi.org/10.1182/blood-2025-729

Published: 2025

Journal Articles

All 19 subjects with transfusion-dependent β-thalassemia achieved transfusion independence after treatment with RM-001 (autologous HBG1/2 promoter-modified CD34+ hematopoietic stem and progenitor cells)

Rongrong Liu, Li Wang, Hui Xu, Jianpei Fang, Sixi Liu, Xiaolin Yin, Junbin Liang, Xinyu Li, Yue Li, Gaohui Yang, Yaoyun Li, Yali Zhou, Lin Cheng, Yongrong Lai, Junjiu Huang, Xinhua Zhang

Blood (2025) 146 (Supplement 1): 4308.

https://doi.org/10.1182/blood-2025-4308

Published: 2025

Journal Articles

A Phase I, open-label study of CTD402, a universal CD7-targeting CAR T-cell therapy, in patients with relapsed/refractory severe aplastic anemia

Lele Zhang, Ruonan Li, Jing Zhang, Jianping Li, Neng Nie, Xingxin Li, Xiao Yu, Zhexiang Kuang, Liyun Li, Jingyu Zhao, Maria del Rosario, Xiao Shi, Yong Yu, Yali Zhou, Ming Gao, Wengang Ge, Jiangtao Ren, Jan Davidson-Moncada, Jun Shi

Blood (2025) 146 (Supplement 1): 3210.

https://doi.org/10.1182/blood-2025-3210

Published: 2025

Journal Articles

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Yong-xian Hu, Xiaoyu Zhu, Heng Mei, Ying Wang, Yali Zhou, Kangqi Bian, Maria del Rosario, Eileen McNulty, Ming Gao, Lu Han, Wengang Ge, Jan Davidson-Moncada, Jiangtao Ren, He Huang

Blood (2025) 146 (Supplement 1): 816.

https://doi.org/10.1182/blood-2025-816

Published: 2025

Journal Articles

Target enrichment long-range sequencing (TLES) reveals structural variations missed by PEM-seq

Shuhui Yu, Yueqiang Wang, Wenxin Zhu, Qin Chen, Biao Wang, Qiang Wu, Yali Zhou, Ling Yuan, Sha Li, Xiaojing Zhang, Mingxi Chen, Mengyao Wang, Liping Zhu, Yajin Ni, Jan Davidson-Moncada, Jiangtao Ren

Blood (2025) 146 (Supplement 1): 4122.

https://doi.org/10.1182/blood-2025-4122

Published: 2025

Journal Articles

CTA311, a universal anti-CD19 CAR t-cell therapy with improved persistence for patients with CD19+ relapsed/ refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL)

Guangyu Sun, Heng Mei, Anyou Wang, Tianzhong Pan, Yali Zhou, Gong Chen, Jiuqin Zeng, Kangqi Bian, Jan Davidson-Moncada, Bo Pei, Lu Han, Jiangtao Ren, Xiaoyu Zhu

Blood (2025) 146 (Supplement 1): 5920.

https://doi.org/10.1182/blood-2025-5920

Published: 2025

Journal Articles

Phase I Study of Allogeneic Anti-CD19 CAR-T Therapy for Patients with CD19+ Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Guangyu Sun, Heng Mei, Yali Zhou, Tianzhong Pan, Lu Han, Jiangtao Ren, Xiaoyu Zhu

Blood (2024) 144 (Supplement 1): 7199.

https://doi.org/10.1182/blood-2024-200582

Published: 2024

Journal Articles

A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

Yongxian Hu, Yali Zhou, Mingming Zhang, Shan Fu, Yong Yu, Ming Gao, Ruimin Hong, Houli Zhao, Lu Han, Jiangtao Ren, He Huang

Blood (2024) 144 (Supplement 1): 921.

https://doi.org/10.1182/blood-2024-207322

Published: 2024

Journal Articles

Updated Safety and Efficacy Results of RM-001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent β-Thalassemia

Rongrong Liu, Li Wang, Hui Xu, Jianpei Fang, Sixi Liu, Xiaolin Yin, Junbin Liang, Xinyu Li, Yue Li, Gaohui Yang, Yaoyun Li, Yali Zhou, Lei Shi, Yongrong Lai, Junjiu Huang, Xinhua Zhang

Blood (2024) 144 (Supplement 1): 4960.

https://doi.org/10.1182/blood-2024-206549

Published: 2024

Journal Articles

Safety and Efficacy of RM-001 (Autologous HBG1/2 Promoter-modified CD34+ Hematopoietic Stem and Progenitor Cells) in Patients with Transfusion-Dependent β-Thalassemia

Rongrong Liu, Li Wang, Hui Xu, Xiaolin Yin, Junbin Liang, Wenqiang Xie, Gaohui Yang, Yaoyun Li, Yali Zhou, Lei Shi, Bin Xiao, Lingling Shi, Zeyan Shi, Xuemei Zhou, Xiangmin Xu, Jianpei Fang, Yongrong Lai, Junjiu Huang, Xinhua Zhang

Blood (2023) 142 (Supplement 1): 4994.

https://doi.org/10.1182/blood-2023-181453

Published: 2023

Journal Articles

A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Xian Zhang, Yali Zhou, Junfang Yang, Jingjing Li, Liyuan Qiu, Wengang Ge, Bo Pei, Jie Chen, Lu Han, Jiangtao Ren, Peihua Lu

Blood (2022) 140 (Supplement 1): 4566–4567.

https://doi.org/10.1182/blood-2022-165733

Published: 2022

Journal Articles

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Yongxian Hu, MD, Yali Zhou, Mingming Zhang, MD, Wengang Ge, Yi Li, MD, Li Yang, MD, Guoqing Wei, MD, Lu Han, Hao Wang, Xingwang Zhang, PhD, Jiangtao Ren, PhD, He Huang, MD PhD

Blood (2020) 136 (Supplement 1): 52.

https://doi.org/10.1182/blood-2020-142262

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Fludarabine, cyclophosphamide, and melphalan (FCM) preconditioning in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia: Update of a prospective, multicenter, single-arm clinical study

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Carfilzomib Augmented with high-dose melphalan conditioning regimen Enhances Response in patients with multiple myeloma eligible for ASCT：an investigator-initiated, prospective, multicenter study

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

A novel reduce toxity myeloablative conditioning regimen f-BMT improves efficacy and safety of allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent thalassemia: A multicenter clinical trial

All 19 subjects with transfusion-dependent β-thalassemia achieved transfusion independence after treatment with RM-001 (autologous HBG1/2 promoter-modified CD34+ hematopoietic stem and progenitor cells)

A Phase I, open-label study of CTD402, a universal CD7-targeting CAR T-cell therapy, in patients with relapsed/refractory severe aplastic anemia

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Target enrichment long-range sequencing (TLES) reveals structural variations missed by PEM-seq

CTA311, a universal anti-CD19 CAR t-cell therapy with improved persistence for patients with CD19+ relapsed/ refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL)

Phase I Study of Allogeneic Anti-CD19 CAR-T Therapy for Patients with CD19+ Relapsed/Refractory Acute B-Lymphoblastic Leukemia

A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

Updated Safety and Efficacy Results of RM-001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent β-Thalassemia

Safety and Efficacy of RM-001 (Autologous HBG1/2 Promoter-modified CD34+ Hematopoietic Stem and Progenitor Cells) in Patients with Transfusion-Dependent β-Thalassemia

A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only